汇宇制药：注射用HY0001a获药物临床试验批准

Core Viewpoint - Huiyu Pharmaceutical's subsidiary Huiyu Haiyue has received approval from the National Medical Products Administration for clinical trials of its innovative drug HY0001a, aimed at treating advanced solid tumors, marking a significant milestone in the company's research and development efforts [1] Group 1 - The clinical trial approval is for the injectable HY0001a, which is an antibody-drug conjugate developed independently by the company [1] - HY0001a is classified as a Class 1 innovative therapeutic biological product [1] - As of the announcement date, there are no approved products targeting the same site in both domestic and international markets, making this the first drug globally to enter clinical trials for this target [1]